Living with Type 1 Diabetes can feel full of challenges, unknowns and constant vigilance. But today, there’s genuine reason for optimism. Researchers at Scripps Research, led by Professor Luc Teyton, have secured a five-year, US $3.2 million grant to explore a new cellular player in the pancreas — vascular-associated fibroblastic cells (VAFs) — that may hold the key to preventing or reversing T1D.

The Discovery That’s Changing the Conversation

Until now, much of the focus in T1D has been on how the immune system attacks insulin-producing beta cells once the process is underway. What Teyton’s team discovered changes that timeline. Their work — published recently in Cell Reports — shows that VAFs, which sit at the boundary of pancreatic islets and blood vessels, are active participants in antigen presentation, a process that signals the immune system. scripps.edu Under normal conditions, VAFs appear to tell immune cells “all is well,” maintaining peace. But when inflammation overwhelms them, their protective signal falters and the immune system may attack the insulin-producing cells.

This means for the first time we’re not just asking why beta-cells are destroyed, but what failed before the destruction began — and how we might stop that failure.

Why This Matters to the T1D Community

Prevention becomes more realistic. If we can act at the stage when VAFs become overwhelmed, we might delay or prevent the onset of T1D instead of only managing it.

Better therapies may emerge. Rather than broadly suppressing the immune system (which carries risks), future treatments might strengthen or restore these pancreatic guard-cells.

Hope for more personalized care. Understanding who is at risk and why may lead to targeted preventive strategies, meaning fewer surprises and more empowerment.

Mental & emotional boost. Living with a chronic condition is draining. Stories like this reinforce that the science is moving forward and you're part of a community where progress is happening.

What to Keep in Mind

Of course, there are caveats:

This research is still in early/preclinical stages. It doesn’t mean an immediate cure is arriving.

Even when therapies emerge, they may not be equally accessible. Equity issues remain a real challenge.

As always with T1D, the day-to-day management remains crucial: insulin, monitoring, healthy habits, emotional support.

Bottom Line

If you live with Type 1 Diabetes, or support someone who does, this is a moment to take a breath of hope. The narrative is shifting: from “we only manage” to “we may prevent or restore”. That’s a big change.

At ThriveWithType1, we’re committed to keeping you informed, connected, and empowered — not just surviving with T1D, but thriving.